Navigation Links
Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Date:8/5/2008

- 88% of patients achieve undetectable HCV RNA levels following 4 weeks of

treatment with R7128 1000mg BID with Pegasys(R) plus Copegus(R) - - Safety and tolerability comparable to placebo administered with Pegasys

plus Copegus -

PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces the preliminary results of the third cohort of a 4-week Phase 1 clinical trial evaluating R7128 1000mg twice daily (BID) in combination with the standard of care (SOC), Pegasys(R) (pegylated interferon) plus Copegus(R) (ribavirin), in 31 treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed in collaboration with Roche.

As previously reported for Cohorts 1 and 2 of this study, R7128 has demonstrated potent short-term antiviral activity and was generally safe and well tolerated at doses of 500mg and 1500mg administered for 28 days in combination with SOC. In Cohort 3, a new formulation of R7128 1000mg BID was administered in combination with SOC. Of the 31 patients enrolled, 25 patients received R7128 1000mg BID and 6 received placebo. 88% (22 of 25) patients receiving R7128 1000mg BID with SOC for 4 weeks achieved undetectable HCV RNA levels (<15 IU/mL). This high rate of Rapid Virologic Response (RVR) compares favorably with the 85% RVR demonstrated earlier this year with R7128 1500mg BID in combination with SOC. Based on these results, R7128 1000mg BID will be among the doses carried forward into Phase 2b studies, which we expect to be submitted to the FDA this Fall.

The preliminary safety and tolerability of R7128 1000mg BID
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department of ... grant to University Hospitals (UH) Case Medical Center Seidman ... national model aimed at improving care for patients with ... the project will test a unique model developed at ... late-stage disease, significant comorbidities, or demonstrated need for high ...
(Date:7/10/2014)... , July 10, 2014 Yesterday, ... Research,s (Moberg) medical device manufacturing facility. Rep. Kennedy ... advanced neurological monitors facilitate cutting-edge research in neurological ... Kennedy and mental health advocate, Garen Staglin ... dedicated to fostering fundamental changes that will radically ...
(Date:7/10/2014)... Mass. , July 10, 2014  Decision ... of surveyed infectious disease (ID) specialists are willing ... Company,s Orbactiv (oritavancin) for use as OPAT, approximately ... prescribe these agents to their hospital inpatients. However, ... of OPAT patients are initiated on OPAT following ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
(Date:7/13/2014)... ANGELES A noninvasive optical imaging device developed ... that later occur in the brain and are ... preliminary results from investigators conducting a clinical trial ... findings July 15 in an oral presentation at ... Denmark. They also were invited by conference organizers ...
(Date:7/13/2014)... Wright & Schulte LLC has learned ... in July of 2015, in U.S. District Court, District ... the discovery process in the South Carolina federal ... over the multidistrict litigation (MDL). The complaints pending in ... who allege that they took the statin medication to ...
(Date:7/13/2014)... 2014 ECS is being ... a parent of a special needs child, I have ... Seattle community for contemporary special education resources and evidence-based ... to students and families in the Seattle metro area ... for special education. We welcome the opportunity to serve ...
(Date:7/13/2014)... According to The Peripheral Neuropathy Program ... program that teaches people how to deal with diabetic ... medications. This program also provides people with safe and ... , including numbness, prickling, burning, and intense stabbing pains. ... home treatment program can help people eliminate some types ...
(Date:7/12/2014)... (PRWEB) July 13, 2014 According to ... Market (Land Systems, Airborne Systems, and Naval Systems) - ... by MarketsandMarkets, Security and Surveillance Radar market are estimated ... to register a CAGR of 5.97% to reach $8.61 ... data tables with 47 figures spread through 161 pages ...
Breaking Medicine News(10 mins):Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4
... Billions of dollars ... tenet of the Hippocratic Oath: First Do No Harm. Ani Kaspar announced today that her ... for Cancer(R). , ... Puerto Rico (PRWEB) February 16, 2010 -- Billions of dollars are spent every year on ...
... ... launch of a new state-of-the-art web-based, Shipping Temperature Electronic Monitoring System - stems. Unique ... is set to revolutionise the management of temperature controlled shipments within the clinical trial ... (PRWEB) ...
... ... wouldn’t be shocked to find an occasional snowman on campus, they probably will be surprised ... Monday, Feb. 22. , ... BRUNSWICK, N.J. – Though students and visitors to Rutgers wouldn’t be shocked to find an ...
... ... solution to the US marketplace. , ... (PRWEB) February 17, 2010 -- Sunquest, ... its Integrated Clinical Environment (Sunquest ICE™) Physician Portal™ solution to the US marketplace. ...
... experts are calling for action to combat the ... of preventable conditions like obesity, diabetes, cardiovascular disease ... CMAJ (Canadian Medical Association Journal) (pre-embargo link ... in Canada have taken little legislative action to ...
... ... to the problem of how certain foods can cause an addictive-like state in the brain ... ... one-day symposium for the Bay Area research community to bring awareness to the problem of ...
Cached Medicine News:Health News:The Voice of Compassionate Cancer Treatment Just Got Louder: Website Provides Resources and a Call to Action for the Medical Community 2Health News:Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials 2Health News:Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials 3Health News:Snowmen Notwithstanding, It's Time To Register For Rutgers' Summer Session 2Health News:Sunquest Introduces Integrated Clinical Environment Physician Portal Solution in US 2Health News:Food and Addiction Symposium on Friday, Feb. 19 2Health News:Food and Addiction Symposium on Friday, Feb. 19 3Health News:Food and Addiction Symposium on Friday, Feb. 19 4
Straight 22 mm serrated jaws. Ring handle with ratchet lock and dull finish. Overall length 4.9 inches...
Straight shafts with 13 mm crisscross serrated platform with polished finish. Wide serrated handle....
Straight shafts with 6.5 mm tying platform. Crisscross serrated 1mm tips. Scalloped handle with dull finish....
Straight shafts with 1 x 2 teeth. Flat handle with haoles and polished finish. Delicate teeth. Most popular size or model....
Medicine Products: